(Q36458543)

14 August 2017

1 reference

title

Insulin resistance--a common link between type 2 diabetes and cardiovascular disease (English)

1 reference

14 August 2017

0 references

1 reference

Harold E Lebovitz

1

1 reference

14 August 2017

1 May 2006

1 reference

Diabetes, Obesity and Metabolism

14 August 2017

1 reference

14 August 2017

8

1 reference

14 August 2017

3

1 reference

14 August 2017

237-249

1 reference

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

14 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

The insulin signalling system and the IRS proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Insulin resistance: definition and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Human obesity: an evolutionary approach to understanding our bulging waistline

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Relationship between visceral fat accumulation and anti-lipolytic action of insulin in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Effect of acute elevation of plasma glycerol, triglyceride and FFA levels on glucose utilization and plasma insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Fatty acids, lipotoxicity and insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

The hormone resistin links obesity to diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Tumor necrosis factor-alpha inhibits insulin's stimulating effect on glucose uptake and endothelium-dependent vasodilation in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

The role of TNFalpha and TNF receptors in obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Tumor necrosis factor-alpha-induced insulin resistance in adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

What are the effects of peroxisome proliferator-activated receptor agonists on adiponectin, tumor necrosis factor-alpha, and other cytokines in insulin resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

The role of TNF-alpha in insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

The adipocyte-secreted protein Acrp30 enhances hepatic insulin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Adiponectin stimulates production of nitric oxide in vascular endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Association of hypoadiponectinemia with impaired vasoreactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Type 2 (non-insulin-dependent) diabetes mellitus and coronary heart disease ? chicken, egg or neither?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Disordered Fat Storage and Mobilization in the Pathogenesis of Insulin Resistance and Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Inflammatory bio-markers and cardiovascular risk prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Effects of current therapeutic interventions on insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Insulin resistance as a therapeutic target for improved endothelial function: metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Thiazolidinediones and blood lipids in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Treatment of diabetic dyslipoproteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Peroxisome proliferator-activated receptors: new targets for the pharmacological modulation of macrophage gene expression and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

(-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

5-aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha/gamma agonists as antidiabetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

MK-0767, a novel dual PPARalpha/gamma agonist, displays robust antihyperglycemic and hypolipidemic activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00521.X

Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy

21 January 2018

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/citations/10.1001/JAMA.260.19.2864

Identifiers

DOI

10.1111/J.1463-1326.2005.00521.X

1 reference

14 August 2017

1 reference

PubMed ID

16634983